Eli Lilly's Taltz+Zepbound Hit Primary Endpoint At Week 36
Phase 3B Data Show Improved One-Year Efficacy For Taltz+Zepbound In Psoriatic Arthritis And Obesity
Related stories
Kraken: Investigating Issue With Flare Funding Gateway. Deposits, Withdrawals May Be Delayed At This Time
L impact | NEWS | Nov 11, 2026, 03:39 PM UTC
SAP Board Member Qi Lu Resigns After US Sanctions On Fund - Handelsblatt, Via DBnews.com
L impact | NEWS | Nov 11, 2026, 03:21 PM UTC
A rally in tech titans pushed stocks higher on speculation that the artificial-intelligence trade that has propelled the bull market has more room to run.
L impact | NEWS | Nov 11, 2026, 03:18 PM UTC
Fear and Greed Index: 37/100 = Fear
L impact | NEWS | Nov 11, 2026, 03:17 PM UTC
Arabica Coffee Futures Hit Over 4-Month low
Arabica coffee futures eased to below $2.7 per pound, reaching their lowest level since June, amid expectations of greater global availability, particularly from top producer Brazi
L impact | NEWS | Nov 11, 2026, 03:13 PM UTC
UK Chancellor Healey On: Use Headroom When You Need It, Rebuild When You Can
L impact | NEWS | Nov 11, 2026, 03:10 PM UTC